NASDAQ:BEAM Beam Therapeutics (BEAM) Stock Price, News & Analysis $23.47 -1.26 (-5.10%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$23.60 +0.13 (+0.56%) As of 10/16/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Beam Therapeutics Stock (NASDAQ:BEAM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Beam Therapeutics alerts:Sign Up Key Stats Today's Range$23.16▼$24.5650-Day Range$23.10▼$31.0352-Week Range$20.23▼$38.26Volume1.65 million shsAverage Volume1.83 million shsMarket Capitalization$2.42 billionP/E RatioN/ADividend YieldN/APrice Target$50.10Consensus RatingModerate Buy Company Overview Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines using base editing, a technology designed to make targeted changes to DNA without cutting both strands of the DNA double helix. The company’s platform is intended to address diseases caused by specific genetic mutations and to support the development of potentially durable treatments. Beam’s research and development activities focus on areas including hematology, liver diseases and genetic disorders. Its pipeline has included investigational programs such as BEAM-101 for sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency and BEAM-301 for glycogen storage disease type Ia. These programs are investigational and remain subject to clinical and regulatory evaluation. Founded in 2017 and headquartered in Cambridge, Massachusetts, Beam was established by scientists and entrepreneurs including David Liu, a pioneer in base-editing technology. John Evans has served as the company’s chief executive officer. Beam’s operations are centered on advancing its proprietary editing platform and developing genetic medicines for patients with serious diseases.AI Generated. May Contain Errors. Read More Beam Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreBEAM MarketRank™: 2.32747223691 of 5 starsBeam Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 624th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingBeam Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 8 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialBeam Therapeutics has a consensus price target of $50.10, representing about 113.5% upside from its current price of $23.47.Amount of Analyst CoverageBeam Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Beam Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Beam Therapeutics are expected to decrease in the coming year, from ($4.49) to ($5.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beam Therapeutics is -27.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beam Therapeutics is -27.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeam Therapeutics has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Beam Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.73% of the float of Beam Therapeutics has been sold short.Short Interest Ratio / Days to CoverBeam Therapeutics has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.Change versus previous monthShort interest in Beam Therapeutics has recently increased by 6.43%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldBeam Therapeutics does not currently pay a dividend.Dividend GrowthBeam Therapeutics does not have a long track record of dividend growth.Read more about Beam Therapeutics' dividend. News and Social Media3.2 / 5News Sentiment0.12 News SentimentBeam Therapeutics has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Beam Therapeutics this week, compared to 6 articles on an average week.Search Interest11 people have searched for BEAM on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat Follows10 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,018,259.00 in company stock.Percentage Held by Insiders3.80% of the stock of Beam Therapeutics is held by insiders.Percentage Held by Institutions99.68% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Beam Therapeutics' insider trading history. Receive BEAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BEAM Stock News HeadlinesCathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?October 17 at 9:00 PM | fool.comBeam Therapeutics (NASDAQ:BEAM) CEO John Evans Sells 25,000 Shares of Company StockOctober 17 at 11:37 AM | insidertrades.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 18 at 1:00 AM | Weiss Ratings (Ad)HC Wainwright Reaffirms Buy Rating for Beam Therapeutics (NASDAQ:BEAM)October 17 at 2:25 AM | americanbankingnews.comBeam Therapeutics (NASDAQ:BEAM) Earns "Outperform" Rating from WedbushOctober 16 at 1:36 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMOctober 15 at 10:00 AM | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX), Beam Therapeutics (BEAM) and Madrigal Pharmaceuticals (MDGL)October 15 at 9:19 AM | theglobeandmail.comMixed beam measurement method could help make ion cancer therapy more preciseOctober 14, 2026 | msn.comSee More Headlines BEAM Stock Analysis - Frequently Asked Questions How have BEAM shares performed this year? Beam Therapeutics' stock was trading at $27.72 on January 1st, 2026. Since then, BEAM shares have decreased by 15.3% and is now trading at $23.47. How were Beam Therapeutics' earnings last quarter? Beam Therapeutics Inc. (NASDAQ:BEAM) announced its quarterly earnings results on Tuesday, August, 4th. The company reported ($1.18) EPS for the quarter, missing analysts' consensus estimates of ($1.11) by $0.07. Beam Therapeutics's revenue for the quarter was down 94.2% compared to the same quarter last year. Does Beam Therapeutics have any subsidiaries? Beam Therapeutics subsidiaries include Blink Therapeutics Inc.. When did Beam Therapeutics IPO? Beam Therapeutics (BEAM) raised $169 million in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 10,588,236 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Beam Therapeutics' major shareholders? Beam Therapeutics' top institutional shareholders include Vontobel Holding Ltd. (0.02%), SteelPeak Wealth LLC (0.02%) and Versant Capital Management Inc. Insiders that own company stock include John M Evans, Fmr Llc, Giuseppe Ciaramella, Christine Bellon, Amy Simon, Terry-Ann Burrell and Bethany J Cavanagh. View institutional ownership trends. How do I buy shares of Beam Therapeutics? Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Beam Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Beam Therapeutics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Tesla (TSLA), Intellia Therapeutics (NTLA) and Editas Medicine (EDIT). Company Calendar Last Earnings8/04/2026Today10/18/2026Study result10/27/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 5 days ago, BEAM's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BEAM CIK1745999 Webwww.beamtx.com Phone857-327-8775FaxN/AEmployees540Year Founded2017Price Target and Rating Average Price Target for Beam Therapeutics$50.10 High Price Target$80.00 Low Price Target$26.00 Potential Upside/Downside+113.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.99 million Net Margins-54.75% Pretax Margin-55.45% Return on Equity-30.71% Return on Assets-24.07% Debt Debt-to-Equity Ratio0.09 Current Ratio14.57 Quick Ratio14.57 Sales & Book Value Annual Sales$156.04 million Price / Sales15.54 Cash FlowN/A Price / Cash FlowN/A Book Value$12.20 per share Price / Book1.92Miscellaneous Outstanding Shares103,288,000Free Float99,363,000Market Cap$2.42 billion OptionableOptionable Beta2.20 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:BEAM) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
